# Analyses médico-économiques de la prise en charge de la maladie coronarienne stable : méta-analyse en réseau et modélisation

Abstract : Stable coronary artery disease is a chronic disease for which many treatment strategies are available, treatment with drugs alone and invasive treatment by stenting or coronary artery bypass graft. With the results of several meta-analyzes showing a mortality rate comparable between treatments, we decided to conduct a research comparing costs. In the first part of my work, we compared, after a period of one year and of 3 years of patient follow-up, clinical and economic data for five treatment of stable angina: medication alone, coronary artery bypass graft, angioplasty without stent, angioplasty with bare metal stent and angioplasty with drug-eluting stent. Mortality and MI rates were our clinical end point. Direct costs related to the treatment performed and related to the management of complications, have been standardized using the purchasing power parity and expressed in U.S. $2008. It was our criterion for economic analysis. A total of 19 clinical studies have been selected in our network meta-analysis. Our results show there is no significant difference in clinical end point. In contrast, we observed a difference in the average cost of each treatment after one year and three year follow-up. The least expensive treatment was the only treatment with drugs, after a year and 3 years of follow-up, each with an average cost per patient of U.S.$ 3,069 and U.S. $13,854. The highest average cost has been obtained with the treatment coronary artery bypass graft: U.S.$ 27,003 after one year and U.S. \$ 28,670 after 3 years of follow-up. However, our conclusions are limited due to the high variability of the economic methods used in the selected studies and because of the evolution of revascularization techniques. In the second part of my research work, we calculated the cost of management of stable angina pectoris patients treated with one of the following four treatment strategies: medication alone, coronary artery bypass graft, angioplasty with bare metal stent and angioplasty with stent active. We defined a part 6 clinical situations corresponding to the possible clinical conditions of the patient one year after the treatment. We have defined the quantities of care consumed for each of these clinical situations. The perspective selected was the statutory health insurance in 2011. The calculated costs were related to hospitalization, ambulatory care and medical transport used to reach the hospital. The drug strategy was the least expensive with an average annual cost of € 1,518, the cost taking into account the probability of occurrence of 6 clinical conditions. Treatment with coronary artery bypass graft was the most expensive of the four treatments studied, with an average annual cost of € 15,237. The prospect of my work is to model the management of stable angina pectoris patient considering a second treatment if the first treatment led to a situation of treatment failure. The trees we built then allow us to perform a cost-effectiveness analysis of two strategies with a total duration of patient follow-up of 2 years. Finally, if our work highlights the economic benefits of drug treatment, we emphasize that these results are obtained after following patients over a short period (1 year and 3 years), while stable angina is a chronic disease where therapeutic strategies may succeed in case of failure to one of the treatments. In addition, we keep in mind that the choice of treatment, whether conservative or by drugs, by invasive myocardial revascularization should be done individually, i.e. taking into account the individual characteristics of each patient.
Keywords :
Document type :
Theses

Cited literature [149 references]

https://tel.archives-ouvertes.fr/tel-00921072
Contributor : Abes Star <>
Submitted on : Thursday, December 19, 2013 - 4:02:38 PM
Last modification on : Thursday, April 11, 2019 - 4:02:23 PM
Long-term archiving on : Thursday, March 20, 2014 - 9:35:40 AM

### File

va_caruba_thibaut.pdf
Version validated by the jury (STAR)

### Identifiers

• HAL Id : tel-00921072, version 1

### Citation

Thibaut Caruba. Analyses médico-économiques de la prise en charge de la maladie coronarienne stable : méta-analyse en réseau et modélisation. Economies et finances. Université René Descartes - Paris V, 2013. Français. ⟨NNT : 2013PA05D005⟩. ⟨tel-00921072⟩

Record views